RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (“CBI”) (Nasdaq Capital Market: CBTE) is pleased to announce that it has acquired all of the outstanding capital stock of Mimotopes Pty Ltd (“Mimotopes”), a global leader in high quality research-grade peptide products and applications for the drug discovery industry. Upon completion of the transaction, Mimotopes’ Executive Director Dr. Paul D’Sylva, was appointed to the Board of Directors of CBTE and installed as Chief Executive Officer of the combined entity. Dr. D’Sylva brings to the company a strong commercial focus and a wealth of experience in capital raising, financial management, and business development.
